Inclusion Criteria |
---|
1. Subject age ≥ 18 years old |
2. Metastatic castration-sensitive prostate cancer patients who have not met standard criteria for disease progression on current systemic therapy |
3. Currently treated with surgical castration or medical castration with GnRH agonists/antagonists, and/or an androgen receptor pathway inhibitor (e.g., abiraterone, enzalutamide, apalutamide, darolutamide) * |
4. ECOG Performance Status ≤ 2 |
5. Not currently adhering to national physical activity guidelines for resistance training, as defined as participating in structured resistance training ≥ two days per week. |
6. Regular access to an electronic device with internet service and ability for video calls |
7. Access to an active MyChart account or the willingness to create an account for the purposes of the trial |
8. Willingness to engage in a home-based resistance exercise program two days per week |
9. Willingness to take creatine monohydrate supplementation or placebo for the duration of the 52-week trial and to avoid taking additional creatine-containing supplementation or other nutritional supplementation during the study period |
10. Willingness to complete and submit weekly supplementation logs to study personnel throughout the duration of the 52-week study via email, text, in person, or verbally verified over the phone |
11. Willingness to complete three in-person assessment sessions (baseline, 24-, and 52-weeks) |
12. Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines |
Exclusion Criteria |
1. Treatment with cytotoxic chemotherapy within 12 weeks prior to enrollment |
2. eGFR < 30 ml/min/1.73m2 |